Table 2.
Summary of selected clinical trials.
| Trial | Therapy Type | Treatment Groups | Number of Patients | Median Survival in Months | Year of Publication |
|---|---|---|---|---|---|
| ESPAC-1 | Adjuvant | 5-FU vs. resection only | 188 | 19.7 vs. 14 | 2001 |
| CONKO-001 | Adjuvant | Gemcitabine vs. resection only | 368 | 13.4 vs. 6.7 | 2007 |
| ESPAC-3 | Adjuvant | 5-FU + folinic acid vs. gemcitabine | 1088 | 23 vs. 23.6 | 2010 |
| PRODIGE | First line for stage IV | FOLFIRINOX vs. gemcitabine | 342 | 11.1 vs. 6.8 | 2011 |
| PRODIGE-24 | Adjuvant | FOLFIRINOX vs. Gemcitabine | 493 | 54.4 vs. 35 | 2017 |